Resources for Health Professionals and Local Public Health

• Anti-Tuberculosis Medication Order Form
• Billing Description Form
• College TB risk assessment form
• Contract Reimbursement Statement
• Interjurisdictional Transfer Form
  • Please contact TB Program at 303-692-2638 to order or have one sent to you
• Order for Medical Evaluation for Tuberculosis
• Tuberculin Skin Test (TST) & Treatment Record Blue Cards
  
  • Please contact TB program at 303-692-2638 to order
• Tuberculin Skin Testing Material (PPD) Order Form
• Tuberculosis Contact Investigation Record
• Tuberculosis Program Authorization for Release of Information
• Tuberculosis Isolation Order
• Tuberculosis Monitoring and Case Management Report (TB-17)

Table of Contents (2004 Revision)

Section 1  Skin Testing

• Who to test (Page 1)
• How to Apply the TB Skin Test (Page 3)
• How to Read/Measure Test Results (Page 5)
• How to Interpret Test Results (Page 7)
• BCG Vaccine (Page 9-11)
• What to do After Interpreting the Skin Test (Page 11)
• Two-Step TB Skin Testing (Page 13)
• Anergy Testing (Page 15)
• References and Resources (Page 16)

Section 2  Latent Tuberculosis Infection (LTBI)

• Who is Eligible for Treatment of Latent TB Infection (LBTI) (Page 1)
• How to Administer LBTI (Page 3)
• Recommended LTBI Drug Treatment Regimens & Dosages (Page 8)
• How to Monitor for Side Effects (Page 10)
• How to Monitor for Compliance with IPT (Page 12)
• References and Resources (Page 13)

Section 3  Active TB

• How to Diagnose (Page 1)
• When is an Active Case Contagious (Page 6)
• Quarantine (Page 7)
• Transmission Prevention Precautions (Page 10)
• How to Treat Active TB-Basic Guidelines (Page 15)
• Treatment Regimens and Doses of Anti-Tuberculosis Drugs (Page 19)
• TB Treatment in Special Situations (Page 27)
• TB Drugs—Adverse Reactions and Monitoring (Page 30)
• Management of Patients With Adverse Reactions to TB Drugs (Page 35)
• Drug-Resistant TB (Page 46)
• How to Motivate People to Comply with Therapy (Page 48)
• Contact Investigation (Page 52)
• Post Treatment Evaluation and Follow-up (Page 64)
• Non-Tuberculous Mycobacteria (Page 65)
• Specimen Collection and Transportation (Page 68)
• References and Resources (Page 72)

Section 4  Reporting Procedures

• What to Report (Page 1)
• Who to Notify Regarding Active/Suspect TB (Page 3)
• References and Resources (Page 4)

Table of Contents (2004 Revision)

Section 5  Administrative Issues

• How to Obtain...
  • Anti-tuberculosis Medications (Page 1)
  • Bacteriology Services (Page 1)
  • Chest X-rays (Page 2)
  • Directly Observed Therapy (Page 3)
  • Effective Language Interpreters (Page 3)
  • Other Laboratory Services (Page 3)
  • Patient and Provider Education Materials (Page 4)
  • Skin Testing Materials (Page 4)
• TB Program Contracting and Reimbursement (Page 5)
• Forms (see appendix below for link to Forms) (Page 12)
• Record Retention (Page 17)
• Technical Assistance (Page 18)
• Educational Materials (Page 19)
• Reference and Resources (Page 25)

Section 6  TB and HIV

• General Comments of TB and HIV
  • When to test for HIV Infection (Page 1)
  • Tuberculosis Skin Testing in HIV Infected Individuals (Page 1)
• HIV Patients with Latent TB Infections
  • Who is Eligible for Treatment of LTBI? (Page 2)
  • Treatment of LTBI in Patients With HIV (Page 2)
  • Treatment Options for LTBI in Patients with HIV (Page 3)
  • Special Situations (Page 4)
  • Monitoring Patients with HIV on Treatment for LTBI (Page 4)
  • Monitoring Compliance with DOPT (Page 4)
• HIV Patients with Active TB
  • General Comments (Page 5)
  • Basic Guidelines for Patients with Active TB and HIV (Page 6)
  • Dosage and Treatment Schedules for Patients with HIV and Active TB  (Page 8)
  • Dosages and Adverse Reactions to TB Medications (Page 9)
  • Paradoxical Reactions (Page 10)
  • Special Situations (Page 10)
  • Infection Control (Page 11)
• References and Resources (see appendix below for Resources links) (Page 12)

• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis 2002
• Colorado Revised Statutes, Title 25 Health/Disease Control, Article 4 Disease Control, Part 5 Tuberculosis
• Colorado Rules & Regulations Pertaining to Epidemic & Communicable Disease Control
• Core Curriculum on Tuberculosis
• Colorado TB Monitoring Report
• Tuberculosis Monitoring and Screening for Long Term Care Facilities In Colorado
• Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

English Forms

• Letter ordering treatment for active TB
• Patient TB treatment contract
• TB patient warning letter for refusing treatment for active TB
• Tuberculosis isolation order
• Termination of tuberculosis isolation order
• Warning letter for TB contact evaluation
• Guidelines for using tools
• How to install new fonts

Burmese Forms

• Letter ordering treatment for active TB
• Patient TB treatment contract
• TB patient warning letter for refusing treatment for active TB
• Tuberculosis isolation order
• Termination of tuberculosis isolation order
• Warning letter for TB contact evaluation
• Burmese True Type Font

Spanish Forms

• Letter ordering treatment for active TB
• Patient TB treatment contract
• TB patient warning letter for refusing treatment for active TB
• Tuberculosis isolation order
• Termination of tuberculosis isolation order
• Warning letter for TB contact evaluation

Somali Forms

• Letter ordering treatment for active TB
• Patient TB treatment contract
• TB patient warning letter for refusing treatment for active TB
• Tuberculosis isolation order
• Termination of tuberculosis isolation order
• Warning letter for TB contact evaluation

• Attachment A
• TB Rules and Statutes - Regulation 4

• TB Control FAQs